RESULTS	Overall survival was significantly improved in women assigned to eribulin ( median 131 months , 95 % CI 118-143 ) compared with TPC ( 106 months , 93-125 ; hazard ratio 081 , 95 % CI 066-099 ; p = 0041 ) .\